Pharmaceutical & Life Sciences News

Insulin Manufacturers to Face Grilling at House Hearing

April 10, 2019, 11:00 AM

The average cost of insulin nearly tripled between 2002 and 2013, and lawmakers have invited drug manufacturers and other players to Capitol Hill to explain the spike. The drug has been tweaked over the years, but the version that diabetics have been using for decades still works fine, observers say.

  • Market Nearly Cornered: Only three companies manufacture insulin, even though the patent on the most basic form of the drug expired a long time ago. Representatives from the three companies—Sanofi, Novo Nordisk, and Eli Lilly—will answer questions from the House Energy and Commerce Committee today.

  • Middlemen to Blame? The hearing...
To read the full article log in. To learn more about a subscription click here.